王树森教授：看 CDK4/6i 前沿进展，探究早期乳腺癌治疗优化策略

文章预览

本文仅供医疗卫生等专业人士参考 内容策划：唐颖 内容审核：于轩 题图来源：丁香园自制 参考文献： [1] Dennis Slamon, et al.Ribociclib and endocrine therapy as adjuvanttreatment in patients with HR+/HER2- earlybreast cancer: primary results from the Phase lll NATALEE trial. 2023 ASCO LBA500. [2] Gabriel N. Hortobagyi, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. 2023 SABCS GS03-03. [3] NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). 2024 ESMO BC 113MO, [4] Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial. 2024 ESMO BC 112 MO. [5] Fou ………………………………